透析通路紫杉醇涂层器械使用后的死亡率:系统评价与荟萃分析
该系统评价与荟萃分析纳入8项随机对照试验,比较紫杉醇涂层球囊血管成形术(n=327)与普通球囊经皮腔内血管成形术(PTA,n=331)治疗失功透析通路的全因死亡率。汇总平均随访13.5个月,两组全因死亡率相似(13.8% vs 11.2%,RR 1.26,95%CI 0.85-1.89,p=0.25;I2=0%),亚组分析显示6、12、24个月随访死亡率均无统计学显著差异。作者结论认为短期至中期随访未见死亡率差异,推荐继续使用紫杉醇涂层球囊。
要点
- 汇总平均随访13.5个月,紫杉醇涂层球囊组与PTA组全因死亡率无统计学显著差异。
- 6、12、24个月随访亚组分析均未显示死亡率显著差异。
- 基于已证实的获益与无伤害证据,作者推荐继续使用紫杉醇涂层球囊治疗失功透析通路。
核心结论
- 紫杉醇涂层球囊与普通球囊PTA治疗失功透析通路在短期至中期随访中全因死亡率无差异。
- 作者基于获益已证实且无伤害证据,推荐继续使用紫杉醇涂层球囊。
研究设计与样本
- 系统评价与荟萃分析,检索截至2019年2月28日,纳入8项随机对照试验。
- 比较紫杉醇涂层球囊血管成形术(n=327)与PTA(n=331),无研究涉及紫杉醇涂层支架。
- 采用随机效应模型汇总死亡率数据,使用卡方检验和I2统计量评估异质性。
主要发现
- 汇总平均随访13.5个月(中位12,范围6-24),紫杉醇涂层球囊组全因死亡率13.8%,PTA组11.2%(RR 1.26,95%CI 0.85-1.89,p=0.25;I2=0%)。
- 6个月随访(8项研究):死亡率5.2% vs 4.8%(RR 1.24,95%CI 0.62-2.47,p=0.55)。
- 12个月随访(6项研究):死亡率6.3% vs 6.0%(RR 1.06,95%CI 0.43-2.63,p=0.90)。
- 24个月随访(3项研究):死亡率19.0% vs 13.5%(RR 1.38,95%CI 0.90-2.12,p=0.14)。
临床怎么用
- 对于失功透析通路,紫杉醇涂层球囊可在短期至中期随访中安全使用,不增加全因死亡风险。
- 临床决策时可参考本荟萃分析结果,但需注意随访时间限于短期至中期。
局限性
- 随访时间限于短期至中期(平均13.5个月),缺乏长期死亡率数据。
- 未涉及紫杉醇涂层支架,结论不能外推至支架。
- 检索截止2019年2月28日,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To report the risk of all-cause mortality in patients who underwent dialysis access treatment using paclitaxel-coated devices compared with percutaneous transluminal angioplasty (PTA) with an uncoated balloon. Materials and Methods: A systematic review and meta-analysis of randomized controlled trials were performed to investigate the mortality outcomes associated with paclitaxel-coated devices in the treatment of patients with a failing dialysis access (last search date February 28, 2019). The primary endpoint was all-cause mortality. This analysis included 8 studies comparing paclitaxel-coated balloon (PCB) angioplasty (n=327) and PTA (n=331) in the treatment of failing dialysis access. None investigated paclitaxel-coated stents. Mortality data were pooled using a random effects model. Statistical heterogeneity was evaluated with a chi-square test and the I2 statistic. Summary statistics are expressed as relative risk ratios (RR) with a 95% confidence interval (CI). Results: At the pooled mean follow-up of 13.5 months (median 12, range 6-24) all-cause mortality was similar in the PCB group (13.8%) compared with PTA (11.2%; RR 1.26, 95% CI 0.85 to 1.89, p=0.25; I2=0%). Subgroup analysis, stratified according to length of follow-up, confirmed that there were no statistically significant differences in mortality at short- and midterm follow-up [6-month (8 studies): 5.2% vs 4.8%, RR 1.24, 95% CI 0.62 to 2.47, p=0.55; 12-month (6 studies): 6.3% vs 6.0%, RR 1.06, 95% CI 0.43 to 2.63, p=0.90; and 24-month (3 studies): 19.0% vs 13.5%, RR 1.38, 95% CI 0.90 to 2.12, p=0.14). Conclusion: The analysis found no difference in short- to midterm mortality among patients treated with a drug-coated balloon compared with PTA. With proven benefit and no evidence of harm, the authors recommend ongoing use of PCB for the failing dialysis access.
引用
- Dinh K, Limmer AM, Paravastu SCV, et al. Mortality After Paclitaxel-Coated Device Use in Dialysis Access: A Systematic Review and Meta-Analysis. J Endovasc Ther. 2019. PMID: 31455140. doi:10.1177/1526602819872154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。